Compound class:
Synthetic organic
Comment: Compound 27 was designed to offer improved clinical potential as a utrophin modulator than either ezutromid (failed at Phase 2) or SMT022357 (terminated at preclinical) [1]. This entry shows the compound without specified stereochemistry, to represent the racemic mixture. (+)-27 is slightly more active than (-)-27 or the racemate in vitro.
Clinical rationale: Up-regulation of utrophin (UTRN; P46939) as being investigated as a disease-modifying approach for Duchenne muscular dystrophy (DMD). In the mdx mouse DMD model, increased levels of utrophin effectively acts as a substitute for the dystrophin (DMD; P11532) that is missing in DMD [2]. |
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
methyl ethyl({2-[3-(trifluoromethyl)phenyl]-1,3-benzoxazol-5-yl})phosphinate |
Database Links | |
GtoPdb PubChem SID | 434122172 |
PubChem CID | 154699445 |
Search Google for chemical match using the InChIKey | MNCZMYLRBLYUPR-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | MNCZMYLRBLYUPR |
UniChem Compound Search for chemical match using the InChIKey | MNCZMYLRBLYUPR-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | MNCZMYLRBLYUPR-UHFFFAOYSA-N |